MYCN-amplification is present in ∼30% of all neuroblastomas and overexpression of N-MYC is sufficient to drive neuroblastoma-like tumors in animal models, highlighting the critical role of this oncogene in neuroblastoma development and progression [4, 5]. The gene discussed is MYCN; the disease is neuroblastoma.